Mineralys Therapeutics, Inc.
MLYS
$25.64
-$0.45-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -349.58M | -151.78M | -154.65M | -171.36M | -190.77M |
| Total Depreciation and Amortization | 39.00K | 50.00K | 59.00K | 61.00K | 57.00K |
| Total Amortization of Deferred Charges | 126.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 209.16M | 8.77M | 9.45M | 10.17M | 7.15M |
| Change in Net Operating Assets | 1.47M | 6.56M | 2.73M | -10.23M | -9.12M |
| Cash from Operations | -138.79M | -136.40M | -142.42M | -171.37M | -192.69M |
| Capital Expenditure | -15.00K | -15.00K | -15.00K | 0.00 | -37.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -484.14M | -341.81M | -389.74M | -202.69M | 27.46M |
| Cash from Investing | -484.16M | -341.82M | -389.75M | -202.69M | 27.42M |
| Total Debt Issued | 97.50M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 563.29M | 426.37M | 591.39M | 494.52M | 199.34M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.37M | -382.00K | -391.00K | -133.00K | -145.00K |
| Cash from Financing | 659.43M | 425.99M | 591.00M | 494.39M | 199.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.48M | -52.23M | 58.83M | 120.32M | 33.93M |